Introduction
============

Phacoemulsification lensectomy[@b1-opth-8-2261] occasionally results in retained lens fragments or the entire crystalline lens dislocating into the vitreous, which increases the risk of postoperative complications and vision loss.[@b2-opth-8-2261],[@b3-opth-8-2261] With an estimated 10 million cataract surgeries performed per year worldwide,[@b4-opth-8-2261] the estimated annual incidence of retained lens fragments is between 10,000--160,000 (mean =85,000). The timing of pars plana vitrectomy (PPV) to remove retained lens fragments is controversial, especially concerning whether, and under what circumstances, a "same day" (SD) (as the cataract surgery) vitrectomy (SD-PPV) might be performed. Optimal management of retained lens fragments has not been determined, but cataract surgeons have been urged to avoid attempting to retrieve retained lens fragments by manipulating the vitreous,[@b5-opth-8-2261],[@b6-opth-8-2261] to prevent complications such as retinal detachment,[@b7-opth-8-2261] and to refer patients to a vitreoretinal surgeon promptly.[@b8-opth-8-2261]--[@b13-opth-8-2261]

Some vitreoretinal surgeons suggest performing an SD-PPV, as they believe this to be the optimal time to remove retained lens fragments.[@b14-opth-8-2261],[@b15-opth-8-2261] However, the logistics of arranging an SD-PPV can be daunting.[@b16-opth-8-2261],[@b17-opth-8-2261] Others feel that SD-PPV is unnecessary, complicates the informed consent process, and may increase the risk of complications.[@b18-opth-8-2261],[@b19-opth-8-2261] A survey of cataract surgeons indicated they believed that 58% of patients had retained lens fragments removed immediately,[@b20-opth-8-2261] far higher than reported by vitreoretinal surgeons, who indicated only 13% (536 of 4,150) of eyes received an SD-PPV.[@b21-opth-8-2261]

Policies for performing SD-PPV differ among facilities. Lack of the necessary equipment and/or the immediate availability of an experienced vitreoretinal surgeon may preclude an SD-PPV.[@b22-opth-8-2261] Preliminary examination of the SD-PPV results in the literature[@b23-opth-8-2261] found that some facilities had good visual acuity (VA) results,[@b22-opth-8-2261],[@b24-opth-8-2261],[@b25-opth-8-2261] while other facilities' results were not as good[@b26-opth-8-2261]--[@b28-opth-8-2261] (data not shown). Reasons for this dichotomy were not clear, but lower rates of increased intraocular pressure (IOP) and cystoid macular edema (CME) with SD-PPV may be related to reduced intraocular inflammation/infection.[@b24-opth-8-2261] Several authors reported better VA and lower rates of complications (including retinal detachment, increased IOP, corneal edema, CME, and intraocular inflammation/infection) among patients who had SD-PPV compared with delayed vitrectomy (DEL-PPV), but these differences were not always statistically significant.[@b25-opth-8-2261],[@b29-opth-8-2261]--[@b31-opth-8-2261] Other authors reported little or no differences in these and other outcomes when comparing SD-PPV and DEL-PPV.[@b32-opth-8-2261]--[@b34-opth-8-2261]

This is our second meta-analysis about vitrectomy timing for retained lens fragments. The first, which included no SD-PPV patients, indicated that prompt DEL-PPV (3 to 7 or possibly 3 to 14 days after cataract surgery) was associated with better VA and fewer cases of previtrectomy and postvitrectomy retinal detachment, increased IOP, and intraocular inflammation/infection compared with later (nonprompt) DEL-PPV.[@b13-opth-8-2261] As in our previous study, the primary outcomes for this meta-analysis were not good VA (\<20/40) and bad VA (≤20/200). Secondary outcomes included retinal detachment, increased IOP, intraocular inflammation/infection, CME, and corneal edema. All outcome data were postvitrectomy, preferably at final examination. The aim of this research was to explore 1) differences in clinical outcomes between SD-PPV and DEL-PPV, 2) the observed heterogeneity in SD-PPV results, and 3) the effect of policy differences on SD-PPV results. Complete citations and greater detail may be found in the first author's doctoral dissertation,[@b21-opth-8-2261] which is available upon request. All references to our previous research are to this dissertation and the authors' previous meta-analysis.[@b13-opth-8-2261]

Materials and methods
=====================

Search strategy
---------------

Details of the article search for the systematic review and meta-analyses of the literature on retained lens fragments timing were described previously[@b13-opth-8-2261],[@b21-opth-8-2261] and are summarized in [Figure S1](#SD1-opth-8-2261){ref-type="supplementary-material"}. The publication date range for the MEDLINE search was January 1, 1985 to July 16, 2013. All study designs were considered, and no previous meta-analysis comparing SD-PPV and DEL-PPV outcomes was found. Internal review board approval and informed consent are not required for a meta-analysis.

Inclusion criteria
------------------

A study was included in the meta-analysis if it contained at least ten patients who received a vitrectomy for intravitreal retained lens fragments after surgery for an age-related cataract; had mean follow-up of at least 3 months; and had results for both SD-PPV and DEL-PPV patients, including the number receiving each treatment (SD-PPV and DEL-PPV), and the number in each treatment group who experienced at least one of the outcomes.

Data extraction
---------------

For each study/outcome combination, the number of patients was recorded, separately for those who did and did not experience that outcome, for SD-PPV and DEL-PPV. Our previous research indicated that when an SD-PPV was not performed, a vitreoretinal surgeon should wait at least 3 days after cataract surgery before attempting a vitrectomy unless severe complications preclude a delay. Therefore, whenever possible, DEL-PPVs were limited to those performed at least 3 days after cataract surgery. Additional details of the data extraction were described previously.[@b13-opth-8-2261],[@b21-opth-8-2261]

Study classification
--------------------

The Mayo Clinic Florida (MCF) SD-PPV policy permits an SD-PPV under a "no move, no wait" policy only if a vitreoretinal surgeon begins the vitrectomy within 15 minutes of cataract surgery and the patient is not moved from the original operating room. In addition, the policy precludes cataract surgeons from attempting to remove intravitreal retained lens fragments.[@b35-opth-8-2261] Based on the information available, articles were classified as MCF+ if their SD-PPVs met criteria similar to those at the MCF and as MCF− if their SD-PPVs did not meet these criteria.

The three criteria were SD-PPVs performed 1) at the same facility as the cataract surgery, 2) with only a short time between cataract surgery and vitrectomy, and 3) without any cataract surgeons attempting to remove the intravitreal retained lens fragments. SD-PPV was coded as "same facility" if the authors indicated immediate vitrectomy, vitrectomy at the time of cataract surgery, or that SD-PPV was possible only if cataract surgery was done in a facility where a vitreoretinal surgeon was available. SD-PPV was coded as "a short time between cataract surgery and vitrectomy" if the authors indicated this explicitly or implied this, for example: immediate, converted to vitrectomy, or same operating room. SD-PPV was coded as "different facility" and/or "not a short time between cataract surgery and vitrectomy" if the above conditions were not met and/or if the authors indicated that some or all of the SD-PPV patients were "referred to our facility". All facilities were coded based on whether the authors indicated that any cataract surgeons attempted to remove intravitreal retained lens fragments for SD-PPV patients during cataract surgery.

Estimating the effect for each study
------------------------------------

The summary effect for the meta-analysis was the risk difference of patients experiencing each outcome between the SD-PPV and DEL-PPV treatment groups. To estimate the risk difference in the population, using sample data from each study, the observed risk was determined by dividing the number of events (occurrence of the adverse outcome, such as retinal detachment) in each treatment group (SD-PPV and DEL-PPV) by the number of patients in that group. The risk difference for each study was the proportion of DEL-PPV patients minus the proportion of SD-PPV patients, so positive numbers "favored" (indicated superior outcomes with) SD-PPV, while negative numbers favored DEL-PPV.

When possible, the variance for each risk difference was estimated using the standard formula for estimating the variance of a risk difference.[@b36-opth-8-2261] However, when there were no events (or no nonevents) in a study treatment group (SD-PPV and/or DEL-PPV), the variance was estimated using the observed proportion of events in the total sample (SD-PPV plus DEL-PPV groups) for that study or the overall proportion of events (in that treatment group) in all studies.[@b21-opth-8-2261] The effect of including studies whose variance was not estimated using the standard formula for estimating the variance of a risk difference was assessed with a sensitivity analysis.

Statistical analyses
--------------------

Meta-analyses were performed using Comprehensive Meta-Analysis, version 2.2 (Biostat Inc., Englewood, NJ, USA). As in our previous research, random-effects models were used in the main meta-analyses. All additional meta-analyses, which compared subgroups of studies, used mixed-effect models, combining studies within subgroups using random-effects models but combined subgroups using fixed-effects models. These mixed-effect models did not assume a common variance across subgroups (no pooling of variance), but rather, the variance in each subgroup was estimated separately. These additional analyses assessed how results differed between MCF+ and MCF− studies and, for MCF+ studies only, by the timing of the DEL-PPV. We also assessed effects of reporting and publication biases, including studies whose variance was not estimated using the standard formula (discussed above), and assessed whether the results were robust with sensitivity analyses.[@b37-opth-8-2261],[@b38-opth-8-2261] Results were statistically significant with *P*-value ≤0.05 and marginally significant with 0.05\<*P*≤0.15.[@b35-opth-8-2261],[@b39-opth-8-2261]

Results
=======

Search results
--------------

A total of 304 articles were identified (230 through PubMed and 74 from other sources, including articles' reference lists), with 128 excluded based on reading the title and abstract. Full text of the remaining 176 articles was retrieved and reviewed. A total of 76 articles were included in the systematic review of the retained lens fragments literature. However, only 23 articles with 21 unique study cohorts had the data necessary for the SD-PPV vs DEL-PPV meta-analysis.

In one article,[@b40-opth-8-2261] there were data for only the study (not the control) group, so only these patients were included. All the patients in Kim et al[@b22-opth-8-2261] and Moore et al[@b7-opth-8-2261] were also in Modi et al[@b32-opth-8-2261] but no patients were double-counted. Modi et al[@b32-opth-8-2261] was used for VA, CME, and corneal edema; Moore et al[@b7-opth-8-2261] was used for retinal detachment; and Kim et al[@b22-opth-8-2261] was used for increased IOP and intraocular inflammation/infection. This was done to preferentially use data for final outcomes rather than for outcomes any time after the vitrectomy. Nine (39%) articles were MCF− and 14 (61%) were MCF+ (see the "Study classification" section). A summary of the initial search results of the "retained lens fragments timing" literature appeared previously.[@b13-opth-8-2261] [Figure 1](#f1-opth-8-2261){ref-type="fig"} contains a summary, in the standard format,[@b41-opth-8-2261] of the updated search results.

[Table 1](#t1-opth-8-2261){ref-type="table"} contains details for the 23 articles (21 studies). The studies' locations were: six of 21 from the USA/Canada (29%), nine from Europe (43%), five from Asia (24%), and one from Australia (5%). Patients were treated from 1988 to 2011, so overall, there were 24 years of service for all the studies collectively, with an average of 6.6 years of service per study (range 1 to 22 years of service). The studies tended to be small, with 17 (81%) including fewer than 100 patients. Collectively, studies included in the meta-analysis had data for 1,606 eyes, with a mean of 76.5 eyes per study (median =25; range 12 to 569 eyes). Of these, 1,596 (99.4%) eyes received a vitrectomy (article range 83% to 100%), and ten eyes (0.6%) received medical management. Of the eyes that received a vitrectomy, 337 (21%) received an SD-PPV and 1,259 (78%) received a DEL-PPV. Approximately 52% of the patients were female, with an average age of 74.2 years (study means range from 54 to 78 years). Including the SD-PPV patients, the average time between cataract surgery and vitrectomy was 13.8 days (study mean range 1.7 to 41 days), and mean follow-up time was approximately 13.6 months (study mean range 3 to 63 months).

Quality analysis
----------------

Overall quality issues were similar to those in our previous meta-analysis.[@b13-opth-8-2261] In 18 (78%) of 23 articles, patients were a consecutive series (a representative sample of the population), but only one (4%) article was a prospective study. In 21 (91%) articles, the years of service were stated, all patients were accounted for, and patients' characteristics at presentation were reported. Reasons were given for all lost/excluded patients in 20 (87%) articles, but in only 17 (74%) articles was information reported on all patients excluded for missing data or loss to follow-up. In 14 (61%) articles, the authors specified standardized assessments of outcomes, and in 13 (57%) articles, the authors indicated their criteria for treatment choice (vitrectomy timing). Only eleven (48%) articles reported preexisting ocular comorbidities and actual *P*-values.

Also, using the Minckler[@b42-opth-8-2261] evidence-based rating system, for clinical importance, 19 (83%) articles were rated A, one (4%) article was rated B, and three articles were rated C (13%). For Minckler's other criterion, strength of evidence, all articles were rated III (weak), mainly because the research was retrospective. Two (9%) articles reported data for all seven outcomes, two (9%) articles for six outcomes, five (22%) articles for five outcomes, three (13%) articles for four outcomes, three (13%) articles for three outcomes, four articles (17%) for two outcomes, and four (17%) articles for one outcome. Five (22%) articles had average follow-up time between 3 and 6 months, nine (39%) articles between 6 and 12 months, six (26%) articles between 12 and 24 months, and three (13%) articles for more than 24 months.

Statistical significance analysis
---------------------------------

Our previous research discussed low statistical power in the retained lens fragments timing literature. The analysis estimating each study's power for comparing outcomes was updated, and the results (mean =24%, median =14%) again indicated that many studies had low power. [Figure 2A](#f2-opth-8-2261){ref-type="fig"} shows whether SD-PPV or DEL-PPV seemed better for each outcome, for all articles with these data.[@b2-opth-8-2261],[@b3-opth-8-2261],[@b6-opth-8-2261],[@b7-opth-8-2261],[@b11-opth-8-2261],[@b12-opth-8-2261],[@b14-opth-8-2261],[@b15-opth-8-2261],[@b17-opth-8-2261]--[@b19-opth-8-2261],[@b22-opth-8-2261],[@b24-opth-8-2261]--[@b27-opth-8-2261],[@b29-opth-8-2261]--[@b31-opth-8-2261],[@b34-opth-8-2261],[@b35-opth-8-2261],[@b40-opth-8-2261],[@b43-opth-8-2261]--[@b45-opth-8-2261] These SD-PPV vs DEL-PPV results appear mixed and do not obviously favor either vitrectomy time.

Main SD-PPV vs DEL-PPV meta-analysis
------------------------------------

These results ([Table 2](#t2-opth-8-2261){ref-type="table"}) favored SD-PPV for all outcomes except bad VA, remembering that a positive risk difference "favored" (indicated superior outcomes with) SD-PPV, while a negative risk difference favored DEL-PPV. However, only one of the results among the outcomes that favored SD-PPV (not good VA, retinal detachment, increased IOP, intraocular inflammation/infection, CME, and corneal edema) was statistically significant. The IOP results indicated a significant risk difference of 7.0% between SD-PPV and DEL-PPV (*P*=0.042 \[*z*-test\], 95% confidence interval = \[0.2% to 13.8%\]). Also, the corneal edema results were heavily influenced by a single case, which was the only SD-PPV patient in one study.[@b6-opth-8-2261] These results do not provide enough evidence to indicate a consistent association between clinical outcomes and vitrectomy timing (SD-PPV or DEL-PPV) and agree with the statistical significance analysis in [Figure 2A](#f2-opth-8-2261){ref-type="fig"}.

Separate MCF+ and MCF− meta-analyses
------------------------------------

Another statistical significance analysis, with studies separated into MCF+ ([Figure 2B](#f2-opth-8-2261){ref-type="fig"}) and MCF− ([Figure 2C](#f2-opth-8-2261){ref-type="fig"}), indicted that SD-PPV might have produced better outcomes in MCF+ studies[@b2-opth-8-2261],[@b7-opth-8-2261],[@b11-opth-8-2261],[@b17-opth-8-2261]--[@b19-opth-8-2261],[@b22-opth-8-2261],[@b24-opth-8-2261],[@b25-opth-8-2261],[@b27-opth-8-2261],[@b30-opth-8-2261],[@b32-opth-8-2261],[@b35-opth-8-2261],[@b40-opth-8-2261],[@b44-opth-8-2261],[@b45-opth-8-2261] but not in MCF− studies.[@b3-opth-8-2261],[@b6-opth-8-2261],[@b12-opth-8-2261],[@b14-opth-8-2261],[@b15-opth-8-2261],[@b26-opth-8-2261],[@b29-opth-8-2261],[@b31-opth-8-2261],[@b34-opth-8-2261],[@b43-opth-8-2261] [Table 3](#t3-opth-8-2261){ref-type="table"} compares the percent of SD-PPV and DEL-PPV patients with each outcome, by MCF policy status. [Figures 2B and 2C](#f2-opth-8-2261){ref-type="fig"}, along with the data in [Table 3](#t3-opth-8-2261){ref-type="table"}, support a hypothesis that the risk differences between immediate SD-PPV and DEL-PPV (in MCF+ studies) more consistently favor SD-PPV than the risk differences between nonimmediate SD-PPV and DEL-PPV (in MCF− studies).

Therefore, meta-analyses were done separately for the MCF+ and MCF− studies, and these results differed from those done with all the studies combined (compare [Tables 2](#t2-opth-8-2261){ref-type="table"} and [4](#t4-opth-8-2261){ref-type="table"}). For the MCF+ studies, all results favored SD-PPV (except intraocular inflammation/infection, which was essentially neutral). For five of seven outcomes (not good VA, bad VA, retinal detachment, increased IOP, and corneal edema), the effect favoring SD-PPV was statistically significant. In the MCF+ studies, the number needed to treat, with immediate SD-PPV rather than DEL-PPV, to avoid all five statistically significant outcomes, was four.[@b36-opth-8-2261] This provided some evidence that immediate SD-PPVs (performed according to policies similar to the MCF SD-PPV policies) produced better outcomes than DEL-PPVs.

For the MCF− studies, three outcomes favored SD-PPV (not good VA, increased IOP, and intraocular inflammation/infection) and four favored DEL-PPV (bad VA, retinal detachment, CME, and corneal edema). The only significant (corneal edema) or marginally significant (bad VA) effects favored DEL-PPV. Based on these mixed, mostly nonsignificant results, there was little evidence to favor either vitrectomy timing (SD-PPV or DEL-PPV) for the MCF− studies, so further analyses were limited to the MCF+ studies only.

An examination of the forest plot from the not good VA meta-analysis ([Figure 3](#f3-opth-8-2261){ref-type="fig"}) visually supported a conclusion that the estimated summary risk difference did not indicate better outcomes with either SD-PPV or DEL-PPV for the MCF− studies (top) but did indicate better outcomes with immediate SD-PPV for the MCF+ studies (bottom). The forest plots for the remaining outcomes (not shown) were similar.

Subgroup analysis: DEL-PPV time after cataract surgery (MCF+ only)
------------------------------------------------------------------

The results of our previous meta-analysis indicated, for vitrectomies performed 3 or more days after cataract surgery, that prompt (earlier) vitrectomies (3 to 7 or 3 to 14 days after cataract surgery) provided better outcomes (for not good VA, bad VA, retinal detachment, increased IOP, and intraocular inflammation/infection).[@b13-opth-8-2261] Based on these results, we investigated whether superior outcomes for immediate SD-PPV (in MCF+ studies) were sensitive to the time until the DEL-PPV. These analyses did not include CME and intraocular inflammation/infection because for these outcomes, there were no significant or marginally significant differences between SD-PPV and DEL-PPV in the MCF+ studies ([Table 4](#t4-opth-8-2261){ref-type="table"}).

### Delayed vitrectomy time periods and data issues

Five DEL-PPV time periods (after cataract surgery) were analyzed. Three time periods were considered "prompt" DEL-PPV (3 to 7, 3 to 14, and 7 to 14 days after cataract surgery), and two time periods were considered "nonprompt" DEL-PPV (7 or more days and 15 or more days after cataract surgery. For studies that provided individual patient data (including the exact day postcataract surgery of the vitrectomy), the time periods were exact. However, for studies that provided data grouped into time intervals, the time periods were based on average (often estimated) times. For these studies, some vitrectomies done on days 1 and 2 after cataract surgery (previously determined to be time needed for the eye to "recover" from cataract surgery)[@b13-opth-8-2261] may have been included in the 3 to 7 and 3 to 14 days, data, and some vitrectomies done in weeks 3 and 4 after cataract surgery may have been included in the 3 to 14 and 7 to 14 days, data. This occurred as long as the average delay was within these time periods because it was impossible to separate the grouped results.

In addition, not every study provided data for each time period. For example, in some studies, no vitrectomies were performed 3 to 7 days after cataract surgery. For each outcome (not good VA, bad VA, retinal detachment, increased IOP, and corneal edema), an initial analysis was performed to estimate a summary effect (risk difference) comparing SD-PPV to various DEL-PPV time periods, including all MCF+ studies with data for any of the DEL-PPV time periods. Summaries of these results are found in the shaded areas of [Table 5](#t5-opth-8-2261){ref-type="table"}. Three subsequent analyses were performed, using only studies that had data for all the time periods being compared. One analysis compared SD-PPV to DEL-PPV performed 3 to 7, 7 to 14, and 15+ days after cataract surgery. The second analysis compared SD-PPV to DEL-PPV performed 3 to 7 and 7+ days after cataract surgery. The third analysis compared SD-PPV to DEL-PPV performed 3 to 14 and 15+ days after cataract surgery. Summaries of these results are found in the unshaded areas of [Table 5](#t5-opth-8-2261){ref-type="table"}. These subsequent comparisons were done because there was a reasonable amount of heterogeneity (ie, between-study variability in effects \[see the *I*-squared statistics in [Table 4](#t4-opth-8-2261){ref-type="table"}\]) in some of the initial MCF+ analyses.

Because the above analyses compared the results for immediate SD-PPVs to only a subset of the DEL-PPVs for each study, the sample size and number of events was often quite small, and there were many studies with no events (or nonevents) in one or both treatment groups. In particular, some corneal edema results were based on only one or two MCF+ studies. Therefore, these results are preliminary and not conclusive.

Detailed results (discussed below) for these analyses are not shown but are available on request. [Figure 4A](#f4-opth-8-2261){ref-type="fig"} shows the median and range of the estimated risk differences for immediate SD-PPV (MCF+) vs prompt DEL-PPV, and [Figure 4B](#f4-opth-8-2261){ref-type="fig"} provides the same information for immediate SD-PPV vs nonprompt DEL-PPV.

### Same-day vs prompt delayed vitrectomies

Overall, these results ([Figure 4A](#f4-opth-8-2261){ref-type="fig"}) show no consistent pattern of risk differences favoring either immediate SD-PPV or prompt DEL-PPV (3 to 7, 3 to 14, or 7 to 14 days after cataract surgery). Of the 35 total comparisons of immediate SD-PPV and prompt DEL-PPV, only one (3%) (favoring immediate SD-PPV) was statistically significant, nine (26%) had *P*-values between 0.05 and 0.50 (eight \[23%\] favoring immediate SD-PPV and one favoring prompt DEL-PPV), and 25 (71%) had *P*-values greater than 0.50, providing little evidence of an association between clinical outcomes and immediate SD-PPV or prompt DEL-PPV. Based on this lack of a consistent pattern in comparisons of immediate SD-PPV and prompt DEL-PPV, there is a preliminary indication that prompt DEL-PPV produces outcomes that are similar to those produced by immediate SD-PPV ([Figures 4A](#f4-opth-8-2261){ref-type="fig"} and [5](#f5-opth-8-2261){ref-type="fig"}).

### Same-day vs nonprompt delayed vitrectomies

However, all 25 results comparing immediate SD-PPV to nonprompt DEL-PPV (7+ and 15+ days after cataract surgery) favored immediate SD-PPV with eight (32%) statistically significant, 14 (56%) with *P*-values between 0.05 and 0.50, and three (12%) with *P*-values greater than 0.50. None favored nonprompt DEL-PPV. This provides a preliminary indication that nonprompt DEL-PPV produces outcomes that may be inferior to those from immediate SD-PPV ([Figures 4B](#f4-opth-8-2261){ref-type="fig"} and [5](#f5-opth-8-2261){ref-type="fig"}).

Results summary
---------------

The SD-PPV vs DEL-PPV results are summarized in [Figure 6](#f6-opth-8-2261){ref-type="fig"}, for all studies ([Figure 6A](#f6-opth-8-2261){ref-type="fig"}) and separately for MCF+ ([Figure 6B](#f6-opth-8-2261){ref-type="fig"}) and MCF− studies ([Figure 6C](#f6-opth-8-2261){ref-type="fig"}). For all studies together and for the MCF− studies, the results did not indicate an association between clinical outcomes and whether the patient had an SD-PPV or DEL-PPV. However, there was evidence that immediate SD-PPV (MCF+ studies) may produce better outcomes than DEL-PPV. These results were robust in analyses for publication/reporting biases and all sensitivity analyses (results not shown).[@b21-opth-8-2261]

Comparisons of immediate SD-PPV with prompt or nonprompt DEL-PPV cannot be considered conclusive, due to small samples, but were congruent with results from our previous meta-analyses.[@b13-opth-8-2261] Comparisons of immediate SD-PPV and prompt DEL-PPV did not consistently favor either vitrectomy time. This supports a preliminary hypothesis that patients who receive a prompt DEL-PPV might enjoy outcomes that are comparable with those who receive an immediate SD-PPV. However, all comparisons of immediate SD-PPV and nonprompt DEL-PPV favored SD-PPV.

Discussion
==========

Patient displeasure is common following complicated cataract surgery[@b46-opth-8-2261],[@b47-opth-8-2261] and tends not to improve if reduced VA persists.[@b48-opth-8-2261] One article reported that, "Most patients \[with retained lens fragments\], who had expected a rapid visual recovery after cataract surgery, were very dissatisfied with poor vision postoperatively."[@b27-opth-8-2261] SD-PPV could help to mitigate this patient dissatisfaction.[@b49-opth-8-2261]

Some authors have suggested that cataract surgery on eyes with increased risk for retained lens fragments be performed at a facility where a vitreoretinal surgeon is available.[@b28-opth-8-2261] One author extended this recommendation to any cataract surgeon learning phacoemulsification.[@b50-opth-8-2261] Our results do not support these suggestions for all cataract surgery patients (although future research may support these for patients with specific risk factors). As long as the cataract surgeon refers the patient to a vitreoretinal surgeon in time for a prompt DEL-PPV (3 to 7 or perhaps 14 days after cataract surgery), our results provide support for current cataract surgery practice patterns and locations.

Previously reported results for SD-PPV were mixed.[@b23-opth-8-2261] Some facilities had good VA results,[@b22-opth-8-2261],[@b24-opth-8-2261],[@b25-opth-8-2261] while other facilities' results were not as good.[@b26-opth-8-2261]--[@b28-opth-8-2261] In one study, six SD-PPV patients had cataract surgery done at a facility with a vitreoretinal unit: one had a massive choroidal hemorrhage, and another had corneal decomposition, possibly "related to prolonged use of intraocular fluids".[@b26-opth-8-2261] Elsewhere, excessive use of infusion fluid was contraindicated to prevent traction and retinal complications.[@b6-opth-8-2261] One study reported no retinal detachments among 38 patients who received an SD (or next-day) vitrectomy,[@b31-opth-8-2261] while, in another study, four of six SD-PPV patients had a retinal detachment.[@b18-opth-8-2261]

The reasons for inconsistent SD-PPV results are not clear, but based on our results, part of the explanation may be that policies and strategies for SD-PPV differ. It is possible that immediate SD-PPV, when cataract surgeons do not attempt retained lens fragment retrieval, produces superior results,[@b35-opth-8-2261] but other SD-PPV strategies may not be as good. Perhaps immediate SD-PPV removes the lens fragments before the onset of time-dependent inflammation and the accompanying choroidal congestion that occurs with same-day patient transfer between surgical facilities. Immediate SD-PPV for retained lens fragments closely resembles a planned pars plana lensectomy, something frequently performed, without complications, by vitreoretinal surgeons. Compared with waiting several hours between surgeries, immediate SD-PPV may take advantage of a clear cornea and minimally inflamed eye to enable better removal of retained lens fragments, with fewer complications. Reasons for inconsistent SD-PPV results might also include characteristics of the eyes and/or surgeons, which could not be explored in a meta-analysis using study-level data.

These results support our previous research on vitrectomy timing. Our previous analysis of MCF SD-PPV vs DEL-PPV data[@b35-opth-8-2261] indicated that immediate SD-PPV was associated with superior clinical outcomes. Our previous meta-analysis, which assessed the effect of increasing vitrectomy delays (3 or more days after cataract surgery), indicated that prompt DEL-PPV outcomes were superior to later (nonprompt) DEL-PPV outcomes.[@b13-opth-8-2261] The current meta-analysis indicated that immediate SD-PPV was associated with superior clinical outcomes compared with all and nonprompt DEL-PPV but that prompt DEL-PPV was associated with outcomes comparable with immediate SD-PPV.

Future research
---------------

This leads to a hypothesis that immediate SD-PPV and prompt DEL-PPV may produce equivalent outcomes. A multicenter, randomized controlled trial would be needed to test a noninferiority hypothesis comparing immediate SD-PPV and prompt DEL-PPV outcomes. Although the MCF policy is one alternative, different facilities may have other successful SD-PPV policies. Further research should analyze how SD-PPV results differ based on various SD-PPV strategies, to determine the optimal circumstances for an SD-PPV.

Study limitations
-----------------

Major limitations include low power due to few patients with adverse events, especially in the SD-PPV group, which was generally much smaller than the DEL-PPV group, and especially in the MCF+ studies ([Table 3](#t3-opth-8-2261){ref-type="table"}). Another limitation was the classification of studies as MCF+ or MCF− based solely on information provided in each article (study-based). It is possible that some SD-PPV patients in the MCF− studies received an immediate SD-PPV, which would undermine the internal validity of MCF+/MCF− comparisons and understate any actual differences between these groups.[@b51-opth-8-2261] Another possible threat to internal validity was selection bias[@b51-opth-8-2261] because it was not possible to determine whether there were significant between-group (SD-PPV vs DEL-PPV) differences in baseline variables. Comparisons of immediate SD-PPV and prompt DEL-PPV (3 to 7, 3 to 14, or 7 to 14 days after cataract surgery) were affected by data grouped into time intervals, so data from DEL-PPV performed outside these time periods were included in some analyses.

Several additional limitations to meta-analysis of these data were discussed previously.[@b13-opth-8-2261] As with our previous meta-analysis, this one had little evidence of publication bias, but the studies did exhibit reporting bias, and it is possible that authors were more likely to report significant, rather than nonsignificant, results. However, sensitivity analyses indicated that the overall conclusions were not affected by reporting bias, the inclusion of small studies and those with no events (or nonevents) in a treatment group, or the removal of any one study from the analyses.[@b21-opth-8-2261]

Clinical recommendations
------------------------

The question of whether SD-PPV for retained lens fragments is appropriate has long been debated by vitreoretinal surgeons, with many firmly on one side (in favor of SD-PPV) and others just as firmly on the other. This research raises the possibility that this lack of consensus may have occurred because all SD-PPVs cannot be considered as the same clinical option. There appears to be at least two distinct variations of SD-PPV: immediate SD-PPV performed under strategies such as the MCF "no move, no wait" policy[@b35-opth-8-2261] and SD-PPV performed under different strategies that permit longer waits and/or interfacility patient transport.

Some ophthalmologists who support SD-PPV may have had good clinical experience with immediate SD-PPV compared with DEL-PPV that occurred weeks, months, or even years after cataract surgery. On the other hand, it is possible that some ophthalmologists who do not support SD-PPV have had experiences with SD-PPV after long delays and/or interfacility patient transport that were not as positive. This meta-analysis may help inform the SD-PPV debate with the contribution that while SD-PPV may be appropriate under some policies (for example, immediately with no waiting or interfacility patient transport), SD-PPV may often be inappropriate under other policies.

Conclusion
==========

This research provides some preliminary evidence that SD-PPV may be unnecessary as long as prompt DEL-PPV would be performed. Some cataract surgery practice patterns can accommodate either immediate SD-PPV or prompt DEL-PPV because the cataract surgeons operate at the same facility as a vitreoretinal surgeon, but most operate where a vitreoretinal surgeon is not readily available. These results, coupled with the results of our previous meta-analysis, provide a preliminary indication that if an immediate SD-PPV cannot be performed, the cataract surgeon need not attempt to transfer the patient to another facility for an SD-PPV, but should refer the patient to a vitreoretinal surgeon so that a prompt DEL-PPV can be performed.

Supplementary materials
=======================

###### 

Original search methods for identification of studies (MEDLINE/PubMed).

**Abbreviations:** AC, anterior chamber; NCBI, National Center for Biotechnology Information.
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![Flowchart of the updated articles search for the systematic review and meta-analyses of the retained lens fragment timing literature with publication dates January 1, 1985 through July 16, 2013.\
**Notes:** Secondary articles contained data for patients who were also in another article.\
**Abbreviations:** CS, cataract surgery; DEL, delayed; MA, meta-analysis; PPV, pars plana vitrectomy; SD, same day; SR, systematic review; VA, visual acuity; vs, versus.](opth-8-2261Fig1){#f1-opth-8-2261}

![Indication of which PPV timing, SD-PPV or DEL-PPV had better outcomes, for all studies (all SD- vs DEL-PPV articles) (**A**), MCF+ studies (**B**), and MCF− studies (**C**).\
**Abbreviations:** CE, corneal edema; CME, cystoid macular edema; DEL-PPV, delayed PPV; IOI, intraocular inflammation/infection; IOP, increased intraocular pressure; MCF, Mayo Clinic Florida; MCF−, studies not adhering to MCF SD-PPV policies; MCF+, studies adhering to MCF SD-PPV policies; PPV, pars plana vitrectomy; RD, retinal detachment; SD-PPV, same-day PPV; VA, visual acuity; vs, versus.](opth-8-2261Fig2){#f2-opth-8-2261}

![Forest plot of a not good VA (\<20/40) mixed-effects model for risk differences comparing SD-PPV and DEL-PPV, separately for MCF+ and MCF− studies.\
**Notes:** Risk difference was the risk for DEL-PPV patients minus the risk for SD-PPV patients. Positive numbers favor SD-PPV. Negative numbers favor DEL-PPV. Squares (size proportional to study weight in the meta-analysis) indicate the estimated risk difference from each individual study, with lines indicating the 95% CI. The red diamond is centered at the overall (all studies') summary estimate of the risk difference. The upper black diamond is centered at the MCF− studies' summary estimate of the risk difference, and the lower black diamond is centered at the MCF+ studies' summary estimate. Each diamond spans its 95% CI.\
**Abbreviations:** CI, confidence interval; DEL, delayed; ID, identification; MCF, Mayo Clinic Florida; MCF−, studies not adhering to MCF SD-PPV policies; MCF+, studies adhering to MCF SD-PPV policies; PPV, pars plana vitrectomy; SD, same day; VA, visual acuity.](opth-8-2261Fig3){#f3-opth-8-2261}

![Comparison of estimated risk differences for immediate SD (MCF+) vs prompt (3 to 7, 3 to 14, or 7 to 14 days after cataract surgery) DEL-PPV (**A**) and nonprompt (7+ or 15+ days after cataract surgery) DEL-PPV (**B**).\
**Notes:** Risk difference is the risk for DEL-PPV patients minus the risk for SD-PPV patients. Positive numbers favor immediate SD-PPV. Negative numbers favor DEL-PPV. Column height indicates median estimated risk differences and error bars represent their range. (**A**) Nonsignificant, mixed results and large ranges support a preliminary hypothesis of similar outcomes for immediate SD- and prompt DEL-PPV. (**B**) Several significant results favoring SD-PPV support previous research that earlier DEL-PPV produces better outcomes.\
**Abbreviations:** CE, corneal edema; DEL, delayed; IOP, increased intraocular pressure; MCF, Mayo Clinic Florida; MCF+, studies adhering to MCF SD-PPV policies; PPV, pars plana vitrectomy; RD, retinal detachment; SD, same day; VA, visual acuity; VAb, bad visual acuity (\<20/200); VAng, not good VA (\<20/40).](opth-8-2261Fig4){#f4-opth-8-2261}

![Indications, from risk differences comparing SD-PPV to prompt and nonprompt DEL-PPV, of which PPV timing produced better clinical outcomes.\
**Notes:** 15+ = nonprompt DEL-PPV 15 or more days after cataract surgery; 3 to 14= prompt DEL-PPV 3 to 14 days after cataract surgery; 3 to 7= prompt DEL-PPV 3 to 7 days after cataract surgery; 7+ = nonprompt DEL-PPV more than 7 days after cataract surgery; 7 to 14= prompt DEL-PPV 7 to 14 days after cataract surgery. The five outcomes were corneal edema, increased intraocular pressure/glaucoma, retinal detachment, bad visual acuity (≤20/200), and not good visual acuity (\<20/40).\
**Abbreviations:** DEL, delayed; PPV, pars plana vitrectomy; SD, same day; vs, versus.](opth-8-2261Fig5){#f5-opth-8-2261}

![Comparison of SD- vs DEL-PPV risk differences for all studies (**A**), MCF+ studies (**B**), and MCF− studies (**C**).\
**Notes:** Risk difference is the risk for DEL-PPV patients minus the risk for SD-PPV patients. Positive numbers favor SD-PPV. Negative numbers favor DEL-PPV. Column height is the estimated risk difference; error bars span its 95% CI. CE results for MCF− studies (outlier not included).\
**Abbreviations:** CE, corneal edema; CI, confidence interval; CME, cystoid macular edema; DEL, delayed; IOI, intraocular inflammation/infection; IOP, increased intraocular pressure; MCF, Mayo Clinic Florida; MCF−, studies not adhering to MCF SD-PPV policies; MCF+, studies adhering to MCF SD-PPV policies; PPV, pars plana vitrectomy; RD, retinal detachment; SD, same day; VAb, bad visual acuity (≤20/200); VAng, not good VA (\<20/40).](opth-8-2261Fig6){#f6-opth-8-2261}

###### 

Description of the 23 articles for the same-day versus delayed vitrectomy meta-analysis

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Article number   Article ID                                     Location (N)           Years of participation   Number of eyes   PPV, N (%)   Patients' ages (years)\   Days CS to PPV[\*](#tfn1-opth-8-2261){ref-type="table-fn"}\   Follow-up (months)\
                                                                                                                                                M/Md/Min/Max              M/Md/Min/max                                                  M/Md/Min/Max
  ---------------- ---------------------------------------------- ---------------------- ------------------------ ---------------- ------------ ------------------------- ------------------------------------------------------------- -------------------------
  1                Ross 1993[@b6-opth-8-2261]                     BC, Canada (1)         \-\--                    12               10 (83)      77/76/53/94               20/12/0/93                                                    16/16/6/26

  2                Kim et al 1994[@b22-opth-8-2261]               FL, USA (1)            1990--1992               62               62 (100)     75/\-\--/51/91            \-\--/\-\--/0/365                                             \-\--/\-\--/\-\--/\-\--

  3                Tommila and Immonen 1995[@b27-opth-8-2261]     Finland (1)            1991--1994               23               23 (100)     75/\-\--/56/89            \-\--/7/0/53                                                  11/\-\--/3/20

  4                Borne et al 1996[@b18-opth-8-2261]             PA, USA (1)            1991--1994               121              121 (100)    75/\-\--/43/92            19/30/0/120                                                   17/\-\--/3/\-\--

  5                Stilma et al 1997[@b26-opth-8-2261]            The Netherlands (11)   1988--1994               70               63 (90)      75/\-\--/47/88            \-\--/\-\--/0/\-\--                                           \-\--/\-\--/3/\-\--

  6                Stenkula et al 1998[@b19-opth-8-2261]          Sweden (2)             1994--1994               19               19 (100)     76/79/58/89               21/20/0/60                                                    11/8/0/24

  7                Watts et al 2000[@b29-opth-8-2261]             Wales (1)              1995--1998               18               18 (100)     74/76/62/87               10/5/0/77                                                     14/12/6/34

  8                Verma et al 2001[@b40-opth-8-2261]             India (1)              1997--1999               12               12 (100)     52/\-\--/40/76            27/\-\--/0/99                                                 3/3/3/3

  9                Hansson and Larsson 2002[@b11-opth-8-2261]     Sweden (1)             1997--2000               66               66 (100)     \-\--/80/41/94            \-\--/3/0/255                                                 \-\--/8/0/30

  10               Yang et al 2002[@b12-opth-8-2261]              Taiwan (2)             1992--1998               25               24 (96)      70/72/40/90               25/17/0/97                                                    10/6/3/44

  11               Moore et al 2003[@b7-opth-8-2261]              Florida (1)            1990--2001               343              343 (100)    \-\--/76/24/100           \-\--/13/0/167                                                \-\--/8/1/96

  12               Stefaniotou et al 2003[@b14-opth-8-2261]       Greece (1)             \-\--                    26               26 (100)     67/\-\--/59/90            \-\--/\-\--/\-\--/\-\--                                       \-\--/\-\--/3/9

  13               Kaynak et al 2006[@b2-opth-8-2261]             Turkey (1)             2002--2003               12               12 (100)     78/\-\--/72/85            4/\-\--/0/7                                                   11/\-\--/9/15

  14               Ruiz-Moreno et al 2006[@b17-opth-8-2261]       Spain (1)              \-\--                    18               18 (100)     71/71/58/87               8/7/0/24                                                      34/45/6/53

  15               Merani et al 2007[@b31-opth-8-2261]            Australia (1)          1998--2003               223              223 (100)    76/78/53/93               10/4/0/132                                                    21/15/0/66

  16               Romero-Aroca et al 2007[@b25-opth-8-2261]      Spain (1)              1997--2005               47               47 (100)     73/\-\--/57/86            \-\--/\-\--/\-\--/\-\--                                       63/\-\--/12/106

  17               Tajunisah and Reddy 2007[@b15-opth-8-2261]     Malaya (1)             2001--2005               22               22 (100)     69/68/52/84               11/5/0/60                                                     9/\-\--/1/24

  18               Chen et al 2008[@b24-opth-8-2261]              Taiwan (1)             2000--2006               78               78 (100)     70/\-\--/24/92            \-\--/\-\--/\-\--/\-\--                                       14/\-\--/5/47

  19               Konstantopoulos et al 2009[@b30-opth-8-2261]   England (1)            2000--2005               17               17 (100)     \-\--/\-\--/\-\--/\-\--   \-\--/\-\--/\-\--/\-\--                                       \-\--/3.35/\-\--/\-\--

  20               Colyer et al 2011[@b34-opth-8-2261]            MD, USA (1)            2005--2008               172              172 (100)    75/\-\--/\-\--/\-\--      15/7/\-\--/\-\--                                              \-\--/\-\--/6/\-\--

  21               Chiang et al 2012[@b3-opth-8-2261]             PA/CA, USA (2)         2006--2011               21               21 (100)     75.5/76/53/97             1.7/1/0/7                                                     3.3/3/2/6

  22               Vanner et al 2012[@b35-opth-8-2261]            FL, USA (1)            1999--2010               35               35 (100)     \-\--/\-\--/\-\--/\-\--   41/30/1/166                                                   48/41/3/124

  23               Modi et al 2013[@b32-opth-8-2261]              FL, USA (1)            1990--2011               569              569 (100)    74.6/\-\--/\-\--/\-\--    \-\--/13.6/0/5,475                                            \-\--/8/0.25/100
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Days between cataract surgery and vitrectomy are for delayed (not same-day) PPV patients only. \-\--Represents missing data.

**Abbreviations:** CS, cataract surgery; ID, identification; M, mean; Max, maximum; Md, median; Min, minimum; PPV, pars plana vitrectomy.

###### 

Main same-day versus delayed vitrectomy meta-analysis results (random effects models) estimated summary risk differences for all studies that had data for that outcome

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Outcome              Studies\   RiskDiff   95% CI            *Z*-score[\*\*](#tfn5-opth-8-2261){ref-type="table-fn"}   *P*-value                                           *I*^2^[\*\*\*](#tfn6-opth-8-2261){ref-type="table-fn"}   SD better[§](#tfn7-opth-8-2261){ref-type="table-fn"}\   DEL better[‡](#tfn8-opth-8-2261){ref-type="table-fn"}\   No difference[\#](#tfn9-opth-8-2261){ref-type="table-fn"}\
                       N                                                                                                                                                                                                              N                                                       N                                                        N
  -------------------- ---------- ---------- ----------------- --------------------------------------------------------- --------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------------
  VA not good          20         10.3%      (−0.4%, 21%)      1.886                                                     0.059[†](#tfn4-opth-8-2261){ref-type="table-fn"}    46.191                                                   12                                                      8                                                        0

  VA bad               15         −0.3%      (−10.7%, 10.1%)   −0.059                                                    0.953                                               52.025                                                   7                                                       7                                                        1

  Retinal detachment   12         3.1%       (−3.0%, 9.3%)     0.995                                                     0.320                                               32.317                                                   7                                                       3                                                        2

  IOP/glaucoma         13         7.0%       (0.2%, 13.8%)     2.031                                                     0.042[\*](#tfn3-opth-8-2261){ref-type="table-fn"}   24.282                                                   8                                                       4                                                        1

  IOI                  11         1.0%       (−1.6%, 3.7%)     0.755                                                     0.450                                               0.000                                                    5                                                       2                                                        4

  CME                  7          1.8%       (−3.1%, 6.7%)     0.732                                                     0.464                                               0.000                                                    5                                                       2                                                        0

  Corneal edema        5          2.6%       (−7.3%, 12.5%)    0.518                                                     0.605                                               68.588                                                   4                                                       1                                                        0
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

*P*≤0.05,

*P*≤0.15 (marginally significant).

Statistic for comparing the risk difference of SD-PPV and DEL-PPV patients.

Indication of heterogeneity among individual study risk difference estimates in the fixed effects model.

Number of studies in which the SD-PPV patients experienced better clinical outcomes;

number of studies in which DEL-PPV patients experienced better clinical outcomes;

number of studies in which there was no difference between the SD-PPV and DEL-PPV clinical outcomes. Risk difference was the risk (of an adverse clinical outcome, such as RD) for DEL-PPV patients minus the risk for SD-PPV patients. Positive numbers favor SD-PPV. Negative numbers favor DEL-PPV. The null hypothesis for the *z*-tests was that the risk difference was equal to zero.

**Abbreviations:** CI, confidence interval; CME, cystoid macular edema; DEL, delayed; IOI, intraocular inflammation/infection; IOP, increased intraocular pressure; PPV, pars plana vitrectomy; RD, retinal detachment; RiskDiff, risk difference; SD, same day; VA, visual acuity.

###### 

Same-day vitrectomy and delayed vitrectomy risk and risk difference for each clinical outcome, separated for MCF− and MCF+ articles

  Article                                   MCF status   Patients, N   Not good visual acuity (\<20/40)   Bad visual acuity (≤20/200)                             Retinal detachment                                      IOP/glaucoma                                              Intraocular inflammation/infection   Cystoid macular edema   Corneal edema                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  ----------------------------------------- ------------ ------------- ---------------------------------- ------------------------------------------------------- ------------------------------------------------------- --------------------------------------------------------- ------------------------------------ ----------------------- --------------- --------------------------------------------------------------- --------------------------------------------------------------- --------------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- -------------- -------------- -------------- -------------- -------------- -------------- ----------- -------------- -------- -----------
  Ross[@b6-opth-8-2261]                     MCF−         1             9                                  0                                                       56                                                      56                                                        0                                    22                      22              0                                                               11                                                              11                                                              0                                                       22                                                      22             0              0              0              0              22             22          100            0        \(100\)
  Stilma et al[@b26-opth-8-2261]            MCF−         6             57                                 67                                                      40                                                      \(26\)                                                    17                                   16                      \(1\)           Not reported                                                    Not reported                                                    0                                                               0                                                       0                                                       Not reported   Not reported                                                                                                   
  Watts et al[@b29-opth-8-2261]             MCF−         5             13                                 20                                                      15                                                      \(5\)                                                     20                                   0                       \(20\)          Not reported                                                    0                                                               15                                                              15                                                      20                                                      8              \(12\)         20             0              \(20\)         Not reported                                       
  Yang et al[@b12-opth-8-2261]              MCF−         1             23                                 100                                                     43                                                      \(57\)                                                    100                                  30                      \(70\)          Not reported                                                    Not reported                                                    0                                                               4                                                       4                                                       Not reported   Not reported                                                                                                   
  Stefaniotou et al[@b14-opth-8-2261]       MCF−         8             18                                 13                                                      44                                                      32                                                        0                                    28                      28              0                                                               17                                                              17                                                              0                                                       44                                                      44             0              11             11             Not reported   Not reported                                       
  Merani et al[@b31-opth-8-2261]            MCF−         14            209                                Not reported                                            Not reported                                            0                                                         4                                    4                       Not reported    Not reported                                                    Not reported                                                    Not reported                                                                                                                                                                                                                                                                                                  
  Tajunisah and Reddy[@b15-opth-8-2261]     MCF−         8             14                                 63                                                      50                                                      \(13\)                                                    50                                   7                       \(43\)          Not reported                                                    Not reported                                                    Not reported                                                    Not reported                                            Not reported                                                                                                                                                                          
  Colyer et al[@b34-opth-8-2261]            MCF−         59            113                                29                                                      35                                                      7                                                         20                                   11                      \(10\)          7                                                               1                                                               \(6\)                                                           5                                                       4                                                       \(1\)          0              2              2              14             13             \(0\)       Not reported            
  Chiang et al[@b3-opth-8-2261]             MCF−         7             14                                 71                                                      64                                                      \(7\)                                                     57                                   14                      \(43\)          14                                                              0                                                               \(14\)                                                          Not reported                                            Not reported                                            Not reported   Not reported                                                                                                   
  **All MCF− articles**                     **n=9**      **109**       **470**                            **36**                                                  **40**                                                  **4**                                                     **24**                               **15**                  **(10)**        **6**                                                           **4**                                                           **(2)**                                                         **4**                                                   **11**                                                  **7**          **1**          **3**          **1**          **14**         **13**         **(1)**     **100**        **0**    **(100)**
  Kim et al[@b22-opth-8-2261]               MCF+         8             54                                 Not used[\*](#tfn12-opth-8-2261){ref-type="table-fn"}   Not used[\*](#tfn12-opth-8-2261){ref-type="table-fn"}   Not used[\*\*](#tfn13-opth-8-2261){ref-type="table-fn"}   0                                    15                      15              0                                                               2                                                               2                                                               Not used[\*](#tfn12-opth-8-2261){ref-type="table-fn"}   Not used[\*](#tfn12-opth-8-2261){ref-type="table-fn"}                                                                                                                                 
  Tommila and Immonen[@b27-opth-8-2261]     MCF+         7             16                                 43                                                      38                                                      \(5\)                                                     Not reported                         Not reported            0               6                                                               6                                                               Not reported                                                    Not reported                                            Not reported                                                                                                                                                                          
  Borne et al[@b18-opth-8-2261]             MCF+         6             115                                50                                                      31                                                      \(19\)                                                    Not reported                         33                      8               \(26\)                                                          0                                                               2                                                               2                                                       Not reported                                            Not reported   0              1              1                                                                                
  Stenkula et al[@b19-opth-8-2261]          MCF+         2             17                                 50                                                      53                                                      3                                                         50                                   29                      \(21\)          0                                                               0                                                               0                                                               50                                                      41                                                      \(9\)          0              6              6              Not reported   Not reported                                       
  Verma et al[@b40-opth-8-2261]             MCF+         3             9                                  0                                                       100                                                     100                                                       0                                    0                       0               Not reported                                                    Not reported                                                    Not reported                                                    Not reported                                            Not reported                                                                                                                                                                          
  Hansson and Larsson[@b11-opth-8-2261]     MCF+         7             59                                 43                                                      47                                                      5                                                         Not reported                         Not reported            Not reported    Not reported                                                    Not reported                                                    Not reported                                                                                                                                                                                                                                                                                                  
  Moore et al[@b7-opth-8-2261]              MCF+         36            307                                Not reported                                            Not reported                                            0                                                         6                                    6                       Not reported    Not reported                                                    Not reported                                                    Not reported                                                                                                                                                                                                                                                                                                  
  Kaynak et al[@b2-opth-8-2261]             MCF+                       11                                 0                                                       9                                                       9                                                         0                                    9                       9               0                                                               0                                                               0                                                               0                                                       0                                                       0              Not reported   Not reported   Not reported                                                                     
  Ruiz-Moreno et al[@b17-opth-8-2261]       MCF+         2             16                                 100                                                     63                                                      \(38\)                                                    0                                    6                       6               0                                                               6                                                               6                                                               50                                                      19                                                      \(31\)         Not reported   Not reported   Not reported                                                                     
  Romero-Aroca et al[@b25-opth-8-2261]      MCF+         9             38                                 22                                                      58                                                      36                                                        Not reported                         Not reported            0               32                                                              32                                                              0                                                               0                                                       0                                                       11             13             2              0              5              5                                                  
  Chen et al[@b24-opth-8-2261]              MCF+         45            33                                 24                                                      61                                                      36                                                        2                                    24                      22              0                                                               18                                                              18                                                              0                                                       21                                                      21             0              0              0              0              9              9           Not reported            
  Konstantopoulos et al[@b30-opth-8-2261]   MCF+         6             11                                 33                                                      64                                                      30                                                        Not reported                         Not reported            Not reported    Not reported                                                    Not reported                                                    Not reported                                                                                                                                                                                                                                                                                                  
  Vanner et al[@b35-opth-8-2261]            MCF+         23            12                                 22                                                      42                                                      20                                                        4                                    25                      21              4                                                               17                                                              12                                                              9                                                       8                                                       \(0\)          9              0              \(9\)          13             25             12          0              8        8
  Modi et al[@b32-opth-8-2261]              MCF+         117           452                                39                                                      42                                                      3                                                         16                                   19                      3               Not reported[\*\*\*](#tfn14-opth-8-2261){ref-type="table-fn"}   Not reported[\*\*\*](#tfn14-opth-8-2261){ref-type="table-fn"}   Not reported[\*\*\*](#tfn14-opth-8-2261){ref-type="table-fn"}   13                                                      13                                                      0              9              17             7                                                                                
  **All MCF+ articles**                     **n=14**     **228**       **789**                            **34**                                                  **44**                                                  **9**                                                     **11**                               **19**                  **8**           **3**                                                           **7**                                                           **5**                                                           **4**                                                   **13**                                                  **9**          **2**          **1**          **(1)**        **10**         **13**         **3**       **7**          **13**   **6**
  **Difference (MCF− minus MCF+)**          **2**        **(4)**       **(5)**                            **13**                                                  **(5)**                                                 **(17)**                                                  **3**                                **(3)**                 **(6)**         **0**                                                           **(2)**                                                         **(2)**                                                         **(1)**                                                 **1**                                                   **2**          **4**          **(0)**        **(4)**        **93**         **(13)**       **(106)**                           

**Notes:** All risks are expressed as percent. () signifies a negative number. Risk difference was the risk (of an adverse clinical outcome, such as RD) for DEL-PPV patients minus the risk for SD-PPV patients. Positive numbers favor SD-PPV. Negative numbers favor DEL-PPV.

Used data from Modi et al 2013;[@b32-opth-8-2261]

used data from Moore et al 2003.[@b7-opth-8-2261]

Final conditions not reported -- used data from Kim et al 1994[@b22-opth-8-2261] or Moore et al 2003.[@b7-opth-8-2261]

**Abbreviations:** DEL, delayed; IOP, increased intraocular pressure; MCF, Mayo Clinic Florida; MCF−, articles not adhering to MCF SD-PPV policies; MCF+, articles adhering to MCF SD-PPV policies; PPV, pars plana vitrectomy; RD, retinal detachment; Risk diff, risk difference; SD, same day.

###### 

Same-day vs delayed vitrectomy meta-analysis results (mixed-effects models) estimated summary risk differences stratified by MCF+/MCF−

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Outcome       Group   Articles\   RiskDiff   95% CI             *Z*-score[⋄](#tfn20-opth-8-2261){ref-type="table-fn"}   *P*-value (z)                                           *I*^2^[⋄⋄](#tfn21-opth-8-2261){ref-type="table-fn"}   Test for BGD: MCF+ vs MCF−   SD better[§](#tfn22-opth-8-2261){ref-type="table-fn"}\   DEL better[‡](#tfn23-opth-8-2261){ref-type="table-fn"}\   No difference[\#](#tfn24-opth-8-2261){ref-type="table-fn"}\        
                        N                                                                                                                                                                                                                                            N                                                        N                                                         N                                                                  
  ------------- ------- ----------- ---------- ------------------ ------------------------------------------------------- ------------------------------------------------------- ----------------------------------------------------- ---------------------------- -------------------------------------------------------- --------------------------------------------------------- ------------------------------------------------------------- ---- ----
  Not good VA   MCF−\   8\          2.1%\      (−12.2%, 16.4%)\   0.285\                                                  0.775\                                                  18.572\                                               1.723                        1                                                        0.189                                                     3\                                                            5\   0\
                MCF+    12          16.2%\     (0.8%, 31.5%)\     2.059                                                   0.039[\*](#tfn16-opth-8-2261){ref-type="table-fn"}      56.864                                                                                                                                                                                                9                                                             3    0
                                    14.1%      = % advantage                                                                                                                                                                                                                                                                                                                                                                                               

  Bad VA        MCF−\   8\          −12.9%\    (−29.8%, 4%)\      −1.494\                                                 0.135[†](#tfn19-opth-8-2261){ref-type="table-fn"}\      45.439\                                               5.097                        1                                                        0.024[\*](#tfn16-opth-8-2261){ref-type="table-fn"}        2\                                                            6\   0\
                MCF+    7           8.5%\      (0.8%, 16.2%)\     2.172                                                   0.030[\*](#tfn16-opth-8-2261){ref-type="table-fn"}      7.572                                                                                                                                                                                                 5                                                             1    1
                                    21.4%      = % advantage                                                                                                                                                                                                                                                                                                                                                                                               

  RD            MCF−\   5\          −1.3%\     (−9.1%, 6.4%)\     −0.333\                                                 0.739\                                                  23.255\                                               2.902                        1                                                        0.088[†](#tfn19-opth-8-2261){ref-type="table-fn"}         3\                                                            2\   0\
                MCF+    7           7.3%\      (1.1%, 13.6%)\     2.302                                                   0.021[\*](#tfn16-opth-8-2261){ref-type="table-fn"}      0.000                                                                                                                                                                                                 4                                                             1    2
                                    8.7%       = % advantage                                                                                                                                                                                                                                                                                                                                                                                               

  IOP           MCF−\   4\          13.4%\     (−8.6%, 35.3%)\    1.195\                                                  0.232\                                                  48.689\                                               0.240                        1                                                        0.624                                                     3\                                                            1\   0\
                MCF+    9           7.6%\      (0.4%, 14.8%)\     2.056                                                   0.040[\*](#tfn16-opth-8-2261){ref-type="table-fn"}      5.354                                                                                                                                                                                                 5                                                             3    1
                                    −5.8%      = % advantage                                                                                                                                                                                                                                                                                                                                                                                               

  IOI           MCF−\   6\          1.7%\      (−1.7%, 5.1%)\     0.972\                                                  0.331\                                                  0.000\                                                0.374                        1                                                        0.541                                                     3\                                                            1\   2\
                MCF+    5           0.0%\      (−4.4%, 4.3%)\     −0.020                                                  0.984                                                   0.000                                                                                                                                                                                                 2                                                             1    2
                                    −1.7%      = % advantage                                                                                                                                                                                                                                                                                                                                                                                               

  CME           MCF−\   3\          −1.4%\     (−11.7%, 8.8%)\    −0.275\                                                 0.783\                                                  0.000\                                                0.502                        1                                                        0.479                                                     1\                                                            2\   0\
                MCF+    4           2.8%\      (−2.77%, 8.3%)\    0.981                                                   0.327                                                   0.000                                                                                                                                                                                                 4                                                             0    0
                                    4.2%       = % advantage                                                                                                                                                                                                                                                                                                                                                                                               

  CE            MCF−\   1\          −100.0%\   (−162%, −38%)\     −3.162\                                                 0.002[\*\*](#tfn17-opth-8-2261){ref-type="table-fn"}\   0.000\                                                10.941                       1                                                        0.001[\*\*\*](#tfn18-opth-8-2261){ref-type="table-fn"}    0\                                                            1\   0\
                MCF+    4           4.9%\      (0.4%, 9.3%)\      2.157                                                   0.031[\*](#tfn16-opth-8-2261){ref-type="table-fn"}      0.000                                                                                                                                                                                                 4                                                             0    0
                                    104.9%     = % advantage                                                                                                                                                                                                                                                                                                                                                                                               
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

*P*≤0.05,

*P*≤0.01,

*P*≤0.001,

*P*≤0.15 (marginally significant).

Statistic for comparing the RiskDiff of SD-PPV and DEL-PPV patients.

Indication of heterogeneity among individual study risk difference estimates in the fixed effects models.

Number of articles in which SD-PPV patients experienced better clinical outcomes;

number of articles in which DEL-PPV patients experienced better clinical outcomes;

number of articles in which there was no difference between SD-PPV and DEL-PPV clinical outcomes. Risk difference was the risk (of an adverse clinical outcome, such as RD) for DEL-PPV patients minus the risk for SD-PPV patients. Positive numbers favor SD-PPV. Negative numbers favor DEL-PPV. The null hypothesis for the *z*-tests was that this risk difference was equal to zero. The null hypothesis for tests of between groups differences (*Q*-value) was that the risk difference in the MCF+ studies was the same as the risk difference in the MCF- studies. The % advantage was the percent advantage of MCF+ articles' SD-PPVs relative to MCF- articles' SD-PPVs over those articles' DEL-PPVs.

**Abbreviations:** BGD, between-groups difference; CE, corneal edema; CI, confidence interval; CME, cystoid macular edema; DEL, delayed; *df*, degrees of freedom; IOI, intraocular inflammation/infection; IOP, increased intraocular pressure; MCF, Mayo Clinic Florida; MCF-, articles not adhering to MCF SD-PPV policies; MCF+, articles adhering to MCF SD-PPV policies; PPV, pars plana vitrectomy; RD, retinal detachment; RiskDiff, risk difference; SD, same day; VA, visual acuity; vs, versus.

###### 

Same-day versus delayed vitrectomy meta-analysis results (mixed-effects models) summary ranges of risk differences by timing of delayed vitrectomy (prompt vs nonprompt) for MCF+ articles only

  Outcome                 Range in risk differences between SD- and DEL-PPV                     
  ----------------------- --------------------------------------------------- -------- -------- --------
  Not good VA (\<20/40)   1.90%                                               6.50%    11.90%   22.60%
  −19.90%                 6.20%                                               8.20%    22.60%   
  Bad VA (≤20/200)        2.20%                                               7.40%    11.70%   13.10%
  −6.90%                  2.80%                                               11.70%   13.10%   
  RD                      −0.10%                                              7.40%    10.60%   12.90%
  −0.20%                  3.90%                                               10.60%   12.90%   
  IOP/Glaucoma            −0.10%                                              22.20%   13.80%   20.80%
  −3.40%                  1.40%                                               13.80%   18.30%   
  Corneal edema           2.80%                                               4.30%    8.50%    14.30%
  0.00%                   2.80%                                               9.10%    14.30%   

**Notes:** Risk difference was the risk (of an adverse clinical outcome, such as RD) for DEL-PPV patients minus the risk for SD-PPV patients. Positive numbers favor SD-PPV. Negative numbers favor DEL-PPV. Shaded areas have results for analyses using articles with data for any of the time periods, while unshaded areas have results for analyses using only articles that had data for all time periods. Nonprompt delayed vitrectomies occurred 7 or more or 15 or more days after cataract surgery. Prompt delayed vitrectomies occurred 3 to 7, 3 to 14, or 7 to 14 days after cataract surgery. All comparisons between same-day vitrectomies and nonprompt delayed vitrectomies favor same-day vitrectomies, while results of comparisons between same-day vitrectomies and prompt delayed vitrectomies were mixed.

**Abbreviations:** DEL, delayed; IOP, increased intraocular pressure; MCF, Mayo Clinic Florida; MCF+, articles adhering to MCF SD-PPV policies; PPV, pars plana vitrectomy; RD, retinal detachment; SD, same day; VA, visual acuity; vs, versus.
